Evidence map›Paper›PMID 37090502›Full record

ArticlebioRxiv : the preprint server for biology2023

Computational design of Matrix Metalloprotenaise-9 (MMP-9) resistant to auto-cleavage.

Alessandro Bonadio, Solomon Oguche, Tali Lavy, Oded Kleifeld, Julia Shifman

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Alessandro BonadioDepartment of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Israel.
Solomon OgucheDepartment of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Israel.
Tali LavyFaculty of Biology, Technion- Israel Institute of Technology, Haifa, Israel.
Oded KleifeldFaculty of Biology, Technion- Israel Institute of Technology, Haifa, Israel.
Julia ShifmanDepartment of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Israel.
Hebrew University of Jerusalem · ILTechnion – Israel Institute of Technology · IL

Funding

Engineering tissue inhibitor of metalloproteinases-2 (TIMP-2) for triple negative breast cancer therapyR01CA258274 · NCI · MAYO CLINIC JACKSONVILLE · PI RADISKY, EVETTE S · 2021 to 2025
$1.6M
NCI NIH HHS R01 CA258274
6 · The paper itself

Abstract

Matrix metalloproteinase-9 (MMP-9) is an endopeptidase that remodels the extracellular matrix and has been implicated as a major driver in cancer metastasis. Hence, there is a high demand for MMP-9 inhibitors for therapeutic purposes. For such drug design efforts, large amounts of MMP-9 are required. Yet, the catalytic domain of MMP-9 (MMP-9

Identifiers

PMID37090502
PMCPMC10120622
OpenAlexW4364360574

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.